- Home
- POLA vs BMRA Comparison
POLA vs BMRA Comparison
Compare POLA & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLA
- BMRA
- Stock Information
- Founded
- POLA 1979
- BMRA 1971
- Country
- POLA United States
- BMRA United States
- Employees
- POLA N/A
- BMRA N/A
- Industry
- POLA Industrial Machinery/Components
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- POLA Miscellaneous
- BMRA Health Care
- Exchange
- POLA Nasdaq
- BMRA Nasdaq
- Market Cap
- POLA N/A
- BMRA 7.4M
- IPO Year
- POLA 2016
- BMRA N/A
- Fundamental
- Price
- POLA $0.45
- BMRA $0.32
- Analyst Decision
- POLA
- BMRA
- Analyst Count
- POLA 0
- BMRA 0
- Target Price
- POLA N/A
- BMRA N/A
- AVG Volume (30 Days)
- POLA 454.1K
- BMRA 68.2K
- Earning Date
- POLA 11-12-2024
- BMRA 10-15-2024
- Dividend Yield
- POLA N/A
- BMRA N/A
- EPS Growth
- POLA N/A
- BMRA N/A
- EPS
- POLA N/A
- BMRA N/A
- Revenue
- POLA $11,950,000.00
- BMRA $5,509,000.00
- Revenue This Year
- POLA $6.72
- BMRA N/A
- Revenue Next Year
- POLA N/A
- BMRA N/A
- P/E Ratio
- POLA N/A
- BMRA N/A
- Revenue Growth
- POLA N/A
- BMRA 1.74
- 52 Week Low
- POLA $0.32
- BMRA $0.24
- 52 Week High
- POLA $0.98
- BMRA $2.13
- Technical
- Relative Strength Index (RSI)
- POLA 49.24
- BMRA 47.45
- Support Level
- POLA $0.44
- BMRA $0.28
- Resistance Level
- POLA $0.54
- BMRA $0.35
- Average True Range (ATR)
- POLA 0.07
- BMRA 0.03
- MACD
- POLA -0.01
- BMRA 0.00
- Stochastic Oscillator
- POLA 20.00
- BMRA 38.50
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.